These findings suggest that EMT may contribute to the immunosuppression in PD-L1-high NSCLC rather than PD-L1-low NSCLC and thus predict a poor response to ICI therapy in PD-L1-high NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.